ID   ST2B1_HUMAN             Reviewed;         365 AA.
AC   O00204; O00205; O75814;
DT   04-JAN-2005, integrated into UniProtKB/Swiss-Prot.
DT   04-JAN-2005, sequence version 2.
DT   07-APR-2021, entry version 181.
DE   RecName: Full=Sulfotransferase 2B1;
DE            EC=2.8.2.2 {ECO:0000269|PubMed:12145317, ECO:0000269|PubMed:12923182, ECO:0000269|PubMed:16855051, ECO:0000269|PubMed:19589875, ECO:0000269|PubMed:21855633, ECO:0000269|PubMed:9799594};
DE   AltName: Full=Alcohol sulfotransferase;
DE   AltName: Full=Hydroxysteroid sulfotransferase 2;
DE   AltName: Full=Sulfotransferase family 2B member 1;
DE   AltName: Full=Sulfotransferase family cytosolic 2B member 1;
DE            Short=ST2B1;
GN   Name=SULT2B1; Synonyms=HSST2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1
RP   AND 2), FUNCTION, TISSUE SPECIFICITY, AND CATALYTIC ACTIVITY.
RC   TISSUE=Placenta;
RX   PubMed=9799594; DOI=10.1006/geno.1998.5518;
RA   Her C., Wood T.C., Eichler E.E., Mohrenweiser H.W., Ramagli L.S.,
RA   Siciliano M.J., Weinshilboum R.M.;
RT   "Human hydroxysteroid sulfotransferase SULT2B1: two enzymes encoded by a
RT   single chromosome 19 gene.";
RL   Genomics 53:284-295(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   FUNCTION (ISOFORMS 1 AND 2), MUTAGENESIS OF 1-MET--ASP-18; 1-MET--ILE-23;
RP   ASP-19; ILE-20; SER-21; GLU-22 AND ILE-23, CATALYTIC ACTIVITY, AND
RP   FUNCTION.
RX   PubMed=12145317; DOI=10.1074/jbc.m207165200;
RA   Fuda H., Lee Y.C., Shimizu C., Javitt N.B., Strott C.A.;
RT   "Mutational analysis of human hydroxysteroid sulfotransferase SULT2B1
RT   isoforms reveals that exon 1B of the SULT2B1 gene produces cholesterol
RT   sulfotransferase, whereas exon 1A yields pregnenolone sulfotransferase.";
RL   J. Biol. Chem. 277:36161-36166(2002).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY, BIOPHYSICOCHEMICAL PROPERTIES,
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION, CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=16855051; DOI=10.1124/dmd.106.011114;
RA   He D., Falany C.N.;
RT   "Characterization of proline-serine-rich carboxyl terminus in human
RT   sulfotransferase 2B1b: immunogenicity, subcellular localization, kinetic
RT   properties, and phosphorylation.";
RL   Drug Metab. Dispos. 34:1749-1755(2006).
RN   [6]
RP   CATALYTIC ACTIVITY, FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=19589875; DOI=10.1124/dmd.108.025759;
RA   Cook I.T., Duniec-Dmuchowski Z., Kocarek T.A., Runge-Morris M.,
RA   Falany C.N.;
RT   "24-hydroxycholesterol sulfation by human cytosolic sulfotransferases:
RT   formation of monosulfates and disulfates, molecular modeling, sulfatase
RT   sensitivity, and inhibition of liver x receptor activation.";
RL   Drug Metab. Dispos. 37:2069-2078(2009).
RN   [7]
RP   BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR LOCATION, PHOSPHORYLATION AT
RP   SER-348, MUTAGENESIS OF SER-347; SER-348; SER-352 AND SER-357, CATALYTIC
RP   ACTIVITY, AND FUNCTION.
RX   PubMed=21855633; DOI=10.1016/j.jsbmb.2011.07.010;
RA   Salman E.D., He D., Runge-Morris M., Kocarek T.A., Falany C.N.;
RT   "Site-directed mutagenesis of human cytosolic sulfotransferase (SULT) 2B1b
RT   to phospho-mimetic Ser348Asp results in an isoform with increased catalytic
RT   activity.";
RL   J. Steroid Biochem. Mol. Biol. 127:315-323(2011).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 19-312 IN COMPLEX WITH
RP   ADENOSINE-3'-5'-DIPHOSPHATE (PAP) AND PREGNENOLONE, CATALYTIC ACTIVITY, AND
RP   FUNCTION.
RX   PubMed=12923182; DOI=10.1074/jbc.m308312200;
RA   Lee K.A., Fuda H., Lee Y.C., Negishi M., Strott C.A., Pedersen L.C.;
RT   "Crystal structure of human cholesterol sulfotransferase (SULT2B1b) in the
RT   presence of pregnenolone and 3'-phosphoadenosine 5'-phosphate. Rationale
RT   for specificity differences between prototypical SULT2A1 and the SULT2BG1
RT   isoforms.";
RL   J. Biol. Chem. 278:44593-44599(2003).
RN   [9]
RP   VARIANTS ARCI14 LEU-149 AND GLN-274, FUNCTION, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=28575648; DOI=10.1016/j.ajhg.2017.05.007;
RA   Heinz L., Kim G.J., Marrakchi S., Christiansen J., Turki H.,
RA   Rauschendorf M.A., Lathrop M., Hausser I., Zimmer A.D., Fischer J.;
RT   "Mutations in SULT2B1 cause autosomal-recessive congenital ichthyosis in
RT   humans.";
RL   Am. J. Hum. Genet. 100:926-939(2017).
CC   -!- FUNCTION: Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate
CC       (PAPS) as sulfonate donor to catalyze the sulfate conjugation.
CC       Responsible for the sulfation of cholesterol (PubMed:19589875,
CC       PubMed:12145317). Catalyzes sulfation of the 3beta-hydroxyl groups of
CC       steroids, such as, pregnenolone and dehydroepiandrosterone (DHEA)
CC       (PubMed:9799594, PubMed:12145317, PubMed:21855633, PubMed:16855051).
CC       Preferentially sulfonates cholesterol, while it has also significant
CC       activity with pregnenolone and DHEA (PubMed:12145317, PubMed:21855633).
CC       Plays a role in epidermal cholesterol metabolism and in the regulation
CC       of epidermal proliferation and differentiation (PubMed:28575648).
CC       {ECO:0000269|PubMed:12145317, ECO:0000269|PubMed:16855051,
CC       ECO:0000269|PubMed:19589875, ECO:0000269|PubMed:21855633,
CC       ECO:0000269|PubMed:28575648, ECO:0000269|PubMed:9799594}.
CC   -!- FUNCTION: [Isoform 2]: Sulfonates pregnenolone but not cholesterol.
CC       {ECO:0000269|PubMed:12145317}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3'-phosphoadenylyl sulfate + an alcohol = adenosine 3',5'-
CC         bisphosphate + an alkyl sulfate + H(+); Xref=Rhea:RHEA:22552,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:30879, ChEBI:CHEBI:58339,
CC         ChEBI:CHEBI:58343, ChEBI:CHEBI:83414; EC=2.8.2.2;
CC         Evidence={ECO:0000269|PubMed:12145317, ECO:0000269|PubMed:16855051,
CC         ECO:0000269|PubMed:19589875, ECO:0000269|PubMed:21855633,
CC         ECO:0000269|PubMed:9799594};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3'-phosphoadenylyl sulfate + 3beta-hydroxyandrost-5-en-17-one
CC         = 3beta-sulfooxy-androst-5-en-17-one + adenosine 3',5'-bisphosphate +
CC         H(+); Xref=Rhea:RHEA:51216, ChEBI:CHEBI:15378, ChEBI:CHEBI:28689,
CC         ChEBI:CHEBI:57905, ChEBI:CHEBI:58339, ChEBI:CHEBI:58343;
CC         Evidence={ECO:0000269|PubMed:12145317, ECO:0000269|PubMed:16855051,
CC         ECO:0000269|PubMed:21855633, ECO:0000269|PubMed:9799594};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:51217;
CC         Evidence={ECO:0000305};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(24S)-hydroxycholesterol + 3'-phosphoadenylyl sulfate = (24S)-
CC         hydroxycholesterol 3-sulfate + adenosine 3',5'-bisphosphate + H(+);
CC         Xref=Rhea:RHEA:52348, ChEBI:CHEBI:15378, ChEBI:CHEBI:34310,
CC         ChEBI:CHEBI:58339, ChEBI:CHEBI:58343, ChEBI:CHEBI:136567;
CC         Evidence={ECO:0000269|PubMed:19589875};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52349;
CC         Evidence={ECO:0000305};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3'-phosphoadenylyl sulfate + cholesterol = adenosine 3',5'-
CC         bisphosphate + cholesterol sulfate + H(+); Xref=Rhea:RHEA:52368,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:16113, ChEBI:CHEBI:58339,
CC         ChEBI:CHEBI:58343, ChEBI:CHEBI:136579;
CC         Evidence={ECO:0000269|PubMed:12145317, ECO:0000269|PubMed:12923182};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52369;
CC         Evidence={ECO:0000305};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3'-phosphoadenylyl sulfate + pregnenolone = adenosine 3',5'-
CC         bisphosphate + H(+) + pregnenolone sulfate; Xref=Rhea:RHEA:52356,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:16581, ChEBI:CHEBI:58339,
CC         ChEBI:CHEBI:58343, ChEBI:CHEBI:133000;
CC         Evidence={ECO:0000269|PubMed:12145317, ECO:0000269|PubMed:12923182,
CC         ECO:0000269|PubMed:21855633};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52357;
CC         Evidence={ECO:0000305};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=23.5 uM for (24S)-hydroxycholesterol
CC         {ECO:0000269|PubMed:19589875};
CC         KM=10.9 uM for DHEA (at 37 degrees Celsius, in the presence of 1 mM
CC         MgCl2) {ECO:0000269|PubMed:21855633};
CC         KM=3.8 uM for DHEA (at 37 degrees Celsius, in the presence of 10 mM
CC         MgCl2) {ECO:0000269|PubMed:16855051};
CC         KM=11.8 uM for pregnenolone (at 37 degrees Celsius, in the presence
CC         of 1 mM MgCl2) {ECO:0000269|PubMed:21855633};
CC         KM=0.6 uM for PAPS (at 37 degrees Celsius, in the presence of 1 mM
CC         MgCl2) {ECO:0000269|PubMed:21855633};
CC         Vmax=1752 pmol/min/mg enzyme toward DHEA (at 37 degrees Celsius, in
CC         the presence of 10 mM MgCl2) {ECO:0000269|PubMed:16855051};
CC       Temperature dependence:
CC         Optimum temperature is 37 degrees Celsius. Retains 70% and 20% of
CC         activity when incubated at 42 degrees Celsius for 45 and 120 minutes,
CC         respectively. Activity is lost after 200 minutes incubation at 42
CC         degrees Celsius. {ECO:0000269|PubMed:16855051,
CC         ECO:0000269|PubMed:21855633};
CC   -!- INTERACTION:
CC       O00204; P14621: ACYP2; NbExp=3; IntAct=EBI-749441, EBI-10198377;
CC       O00204; Q96D03: DDIT4L; NbExp=3; IntAct=EBI-749441, EBI-742054;
CC       O00204; Q96Q35: FLACC1; NbExp=8; IntAct=EBI-749441, EBI-750451;
CC       O00204; Q96Q35-2: FLACC1; NbExp=8; IntAct=EBI-749441, EBI-11533409;
CC       O00204; Q9P2G9-2: KLHL8; NbExp=3; IntAct=EBI-749441, EBI-11959635;
CC       O00204; O43900: PRICKLE3; NbExp=3; IntAct=EBI-749441, EBI-1751761;
CC       O00204; Q04864-2: REL; NbExp=3; IntAct=EBI-749441, EBI-10829018;
CC       O00204; O76094: SRP72; NbExp=3; IntAct=EBI-749441, EBI-1058850;
CC       O00204; P50225: SULT1A1; NbExp=7; IntAct=EBI-749441, EBI-2814403;
CC       O00204; O43704: SULT1B1; NbExp=9; IntAct=EBI-749441, EBI-10179062;
CC       O00204; Q6IMI6: SULT1C3; NbExp=3; IntAct=EBI-749441, EBI-12837366;
CC       O00204; Q6ZNH5: ZNF497; NbExp=3; IntAct=EBI-749441, EBI-10486136;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:12923182,
CC       ECO:0000269|PubMed:16855051, ECO:0000269|PubMed:21855633,
CC       ECO:0000269|PubMed:28575648}. Microsome {ECO:0000269|PubMed:16855051,
CC       ECO:0000269|PubMed:21855633}. Nucleus {ECO:0000269|PubMed:16855051,
CC       ECO:0000269|PubMed:21855633}. Note=Phosphorylation of Ser-348 is
CC       required for translocation to the nucleus.
CC       {ECO:0000269|PubMed:21855633}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=SULT2B1b, B;
CC         IsoId=O00204-1; Sequence=Displayed;
CC       Name=2; Synonyms=SULT2B1a, A;
CC         IsoId=O00204-2; Sequence=VSP_012510;
CC   -!- TISSUE SPECIFICITY: Expressed in the stratum granulosum-stratum corneum
CC       junction in the skin (at protein level) (PubMed:28575648). Expressed
CC       highly in placenta, prostate and trachea and lower expression in the
CC       small intestine and lung (PubMed:9799594).
CC       {ECO:0000269|PubMed:28575648, ECO:0000269|PubMed:9799594}.
CC   -!- DOMAIN: The C-terminus, which contains a proline/serine-rich region is
CC       involved in nuclear translocation and enzymatic thermostability.
CC       {ECO:0000269|PubMed:16855051}.
CC   -!- PTM: Phosphorylated. {ECO:0000269|PubMed:16855051}.
CC   -!- DISEASE: Ichthyosis, congenital, autosomal recessive 14 (ARCI14)
CC       [MIM:617571]: A form of autosomal recessive congenital ichthyosis, a
CC       disorder of keratinization with abnormal differentiation and
CC       desquamation of the epidermis, resulting in abnormal skin scaling over
CC       the whole body. The main skin phenotypes are lamellar ichthyosis (LI)
CC       and non-bullous congenital ichthyosiform erythroderma (NCIE), although
CC       phenotypic overlap within the same patient or among patients from the
CC       same family can occur. Lamellar ichthyosis is a condition often
CC       associated with an embedment in a collodion-like membrane at birth;
CC       skin scales later develop, covering the entire body surface. Non-
CC       bullous congenital ichthyosiform erythroderma characterized by fine
CC       whitish scaling on an erythrodermal background; larger brownish scales
CC       are present on the buttocks, neck and legs.
CC       {ECO:0000269|PubMed:28575648}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the sulfotransferase 1 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U92314; AAC78498.1; -; mRNA.
DR   EMBL; U92315; AAC78499.1; -; mRNA.
DR   EMBL; U92322; AAC78553.1; -; Genomic_DNA.
DR   EMBL; U92316; AAC78553.1; JOINED; Genomic_DNA.
DR   EMBL; U92318; AAC78553.1; JOINED; Genomic_DNA.
DR   EMBL; U92319; AAC78553.1; JOINED; Genomic_DNA.
DR   EMBL; U92320; AAC78553.1; JOINED; Genomic_DNA.
DR   EMBL; U92321; AAC78553.1; JOINED; Genomic_DNA.
DR   EMBL; U92322; AAC78554.1; -; Genomic_DNA.
DR   EMBL; U92316; AAC78554.1; JOINED; Genomic_DNA.
DR   EMBL; U92317; AAC78554.1; JOINED; Genomic_DNA.
DR   EMBL; U92318; AAC78554.1; JOINED; Genomic_DNA.
DR   EMBL; U92319; AAC78554.1; JOINED; Genomic_DNA.
DR   EMBL; U92320; AAC78554.1; JOINED; Genomic_DNA.
DR   EMBL; U92321; AAC78554.1; JOINED; Genomic_DNA.
DR   EMBL; AC008403; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC034694; AAH34694.1; -; mRNA.
DR   CCDS; CCDS12723.1; -. [O00204-1]
DR   CCDS; CCDS12724.1; -. [O00204-2]
DR   RefSeq; NP_004596.2; NM_004605.2. [O00204-2]
DR   RefSeq; NP_814444.1; NM_177973.1. [O00204-1]
DR   PDB; 1Q1Q; X-ray; 2.91 A; A=24-365.
DR   PDB; 1Q1Z; X-ray; 2.40 A; A=19-312.
DR   PDB; 1Q20; X-ray; 2.30 A; A=19-312.
DR   PDB; 1Q22; X-ray; 2.50 A; A=19-312.
DR   PDBsum; 1Q1Q; -.
DR   PDBsum; 1Q1Z; -.
DR   PDBsum; 1Q20; -.
DR   PDBsum; 1Q22; -.
DR   SMR; O00204; -.
DR   BioGRID; 112689; 21.
DR   IntAct; O00204; 17.
DR   STRING; 9606.ENSP00000201586; -.
DR   ChEMBL; CHEMBL1743297; -.
DR   DrugBank; DB01812; Adenosine 3',5'-diphosphate.
DR   DrugBank; DB03309; N-cyclohexyltaurine.
DR   DrugBank; DB01708; Prasterone.
DR   DrugBank; DB02789; Pregnenolone.
DR   SwissLipids; SLP:000001653; -. [O00204-1]
DR   SwissLipids; SLP:000001654; -. [O00204-2]
DR   MoonDB; O00204; Predicted.
DR   iPTMnet; O00204; -.
DR   PhosphoSitePlus; O00204; -.
DR   BioMuta; SULT2B1; -.
DR   jPOST; O00204; -.
DR   MassIVE; O00204; -.
DR   MaxQB; O00204; -.
DR   PaxDb; O00204; -.
DR   PeptideAtlas; O00204; -.
DR   PRIDE; O00204; -.
DR   ProteomicsDB; 47777; -. [O00204-1]
DR   ProteomicsDB; 47778; -. [O00204-2]
DR   Antibodypedia; 31732; 256 antibodies.
DR   DNASU; 6820; -.
DR   Ensembl; ENST00000201586; ENSP00000201586; ENSG00000088002. [O00204-1]
DR   Ensembl; ENST00000323090; ENSP00000312880; ENSG00000088002. [O00204-2]
DR   GeneID; 6820; -.
DR   KEGG; hsa:6820; -.
DR   UCSC; uc002pjl.4; human. [O00204-1]
DR   CTD; 6820; -.
DR   DisGeNET; 6820; -.
DR   GeneCards; SULT2B1; -.
DR   HGNC; HGNC:11459; SULT2B1.
DR   HPA; ENSG00000088002; Tissue enhanced (esophagus, lymphoid tissue, tongue).
DR   MalaCards; SULT2B1; -.
DR   MIM; 604125; gene.
DR   MIM; 617571; phenotype.
DR   neXtProt; NX_O00204; -.
DR   OpenTargets; ENSG00000088002; -.
DR   Orphanet; 313; Lamellar ichthyosis.
DR   PharmGKB; PA36249; -.
DR   VEuPathDB; HostDB:ENSG00000088002.11; -.
DR   eggNOG; KOG1584; Eukaryota.
DR   GeneTree; ENSGT00940000159269; -.
DR   HOGENOM; CLU_027239_1_0_1; -.
DR   InParanoid; O00204; -.
DR   OMA; FCDGNCT; -.
DR   OrthoDB; 780670at2759; -.
DR   PhylomeDB; O00204; -.
DR   TreeFam; TF321745; -.
DR   BioCyc; MetaCyc:HS01587-MONOMER; -.
DR   PathwayCommons; O00204; -.
DR   Reactome; R-HSA-156584; Cytosolic sulfonation of small molecules.
DR   SABIO-RK; O00204; -.
DR   BioGRID-ORCS; 6820; 10 hits in 988 CRISPR screens.
DR   ChiTaRS; SULT2B1; human.
DR   EvolutionaryTrace; O00204; -.
DR   GeneWiki; SULT2B1; -.
DR   GenomeRNAi; 6820; -.
DR   Pharos; O00204; Tbio.
DR   PRO; PR:O00204; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; O00204; protein.
DR   Bgee; ENSG00000088002; Expressed in lower esophagus mucosa and 165 other tissues.
DR   Genevisible; O00204; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-KW.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0004027; F:alcohol sulfotransferase activity; IEA:UniProtKB-EC.
DR   GO; GO:0015485; F:cholesterol binding; IDA:CAFA.
DR   GO; GO:0003676; F:nucleic acid binding; IMP:CAFA.
DR   GO; GO:1990239; F:steroid hormone binding; IMP:CAFA.
DR   GO; GO:0050294; F:steroid sulfotransferase activity; IDA:UniProtKB.
DR   GO; GO:0008146; F:sulfotransferase activity; IBA:GO_Central.
DR   GO; GO:0050427; P:3'-phosphoadenosine 5'-phosphosulfate metabolic process; IDA:CAFA.
DR   GO; GO:0008203; P:cholesterol metabolic process; IMP:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:0045606; P:positive regulation of epidermal cell differentiation; IMP:UniProtKB.
DR   GO; GO:0008202; P:steroid metabolic process; IDA:UniProtKB.
DR   GO; GO:0051923; P:sulfation; IBA:GO_Central.
DR   DisProt; DP00404; -.
DR   DisProt; DP01099; -. [O00204-2]
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR000863; Sulfotransferase_dom.
DR   Pfam; PF00685; Sulfotransfer_1; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cytoplasm; Disease variant;
KW   Endoplasmic reticulum; Ichthyosis; Lipid metabolism; Microsome; Nucleus;
KW   Phosphoprotein; Reference proteome; Steroid metabolism; Transferase.
FT   CHAIN           1..365
FT                   /note="Sulfotransferase 2B1"
FT                   /id="PRO_0000085149"
FT   NP_BIND         70..75
FT                   /note="PAPS"
FT                   /evidence="ECO:0000250|UniProtKB:P49891"
FT   NP_BIND         244..249
FT                   /note="PAPS"
FT                   /evidence="ECO:0000250|UniProtKB:P49891"
FT   NP_BIND         274..276
FT                   /note="PAPS"
FT                   /evidence="ECO:0000250|UniProtKB:P49891"
FT   COMPBIAS        305..365
FT                   /note="Pro/Ser-rich"
FT   ACT_SITE        125
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250|UniProtKB:P49891"
FT   BINDING         98
FT                   /note="Substrate"
FT   BINDING         103
FT                   /note="Substrate"
FT   BINDING         125
FT                   /note="Substrate"
FT   BINDING         147
FT                   /note="PAPS"
FT                   /evidence="ECO:0000250|UniProtKB:P49891"
FT   BINDING         155
FT                   /note="PAPS"
FT                   /evidence="ECO:0000250|UniProtKB:P49891"
FT   BINDING         210
FT                   /note="PAPS"
FT                   /evidence="ECO:0000250|UniProtKB:P49891"
FT   MOD_RES         348
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:21855633"
FT   VAR_SEQ         1..23
FT                   /note="MDGPAEPQIPGLWDTYEDDISEI -> MASPPPFH (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9799594"
FT                   /id="VSP_012510"
FT   VARIANT         51
FT                   /note="L -> S (in dbSNP:rs16982149)"
FT                   /id="VAR_020887"
FT   VARIANT         149
FT                   /note="P -> L (in ARCI14; unknown pathological
FT                   significance; dbSNP:rs1114167424)"
FT                   /evidence="ECO:0000269|PubMed:28575648"
FT                   /id="VAR_079210"
FT   VARIANT         240
FT                   /note="V -> I (in dbSNP:rs2302947)"
FT                   /id="VAR_021988"
FT   VARIANT         274
FT                   /note="R -> Q (in ARCI14; unknown pathological
FT                   significance; dbSNP:rs762765702)"
FT                   /evidence="ECO:0000269|PubMed:28575648"
FT                   /id="VAR_079211"
FT   VARIANT         345
FT                   /note="P -> L (in dbSNP:rs17842463)"
FT                   /id="VAR_020888"
FT   MUTAGEN         1..23
FT                   /note="Missing: Loss of the cholesterol sulfotransferase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:12145317"
FT   MUTAGEN         1..18
FT                   /note="Missing: Increases the cholesterol sulfotransferase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:12145317"
FT   MUTAGEN         19
FT                   /note="D->A: Increases the cholesterol sulfotransferase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:12145317"
FT   MUTAGEN         20
FT                   /note="I->A: Loss of the cholesterol sulfotransferase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:12145317"
FT   MUTAGEN         21
FT                   /note="S->A: Increases the cholesterol sulfotransferase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:12145317"
FT   MUTAGEN         22
FT                   /note="E->A: Increases the cholesterol sulfotransferase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:12145317"
FT   MUTAGEN         23
FT                   /note="I->A: Loss of the cholesterol sulfotransferase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:12145317"
FT   MUTAGEN         347
FT                   /note="S->A: No change in subcellular localization."
FT                   /evidence="ECO:0000269|PubMed:21855633"
FT   MUTAGEN         348
FT                   /note="S->D: 10-fold increase in specific activity for DHEA
FT                   sulfation. 10-fold increase in substrate affinity for DHEA
FT                   and pregnenolone. No effect on substrate affinity for PAPS.
FT                   Increases enzyme stability."
FT                   /evidence="ECO:0000269|PubMed:21855633"
FT   MUTAGEN         348
FT                   /note="S->G: Abolishes nuclear localization."
FT                   /evidence="ECO:0000269|PubMed:21855633"
FT   MUTAGEN         352
FT                   /note="S->G: No change in subcellular localization."
FT                   /evidence="ECO:0000269|PubMed:21855633"
FT   MUTAGEN         357
FT                   /note="S->G: No change in subcellular localization."
FT                   /evidence="ECO:0000269|PubMed:21855633"
FT   CONFLICT        350
FT                   /note="S -> N (in Ref. 1; AAC78498)"
FT                   /evidence="ECO:0000305"
FT   HELIX           19..25
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   STRAND          31..34
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   STRAND          37..41
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   HELIX           46..54
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   STRAND          63..68
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   HELIX           73..84
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   TURN            85..87
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   HELIX           90..94
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   HELIX           97..100
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   STRAND          103..106
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   HELIX           110..112
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   STRAND          121..124
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   TURN            128..130
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   HELIX           133..135
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   STRAND          141..146
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   HELIX           149..162
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   STRAND          163..166
FT                   /evidence="ECO:0007744|PDB:1Q1Z"
FT   HELIX           172..180
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   HELIX           189..196
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   HELIX           197..199
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   STRAND          205..209
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   HELIX           210..215
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   HELIX           217..228
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   HELIX           234..244
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   HELIX           246..250
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   TURN            253..255
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   TURN            256..259
FT                   /evidence="ECO:0007744|PDB:1Q1Z"
FT   TURN            262..264
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   TURN            267..269
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   HELIX           280..283
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   HELIX           287..300
FT                   /evidence="ECO:0007744|PDB:1Q20"
FT   TURN            301..303
FT                   /evidence="ECO:0007744|PDB:1Q20"
SQ   SEQUENCE   365 AA;  41308 MW;  13E95248DD40DF91 CRC64;
     MDGPAEPQIP GLWDTYEDDI SEISQKLPGE YFRYKGVPFP VGLYSLESIS LAENTQDVRD
     DDIFIITYPK SGTTWMIEII CLILKEGDPS WIRSVPIWER APWCETIVGA FSLPDQYSPR
     LMSSHLPIQI FTKAFFSSKA KVIYMGRNPR DVVVSLYHYS KIAGQLKDPG TPDQFLRDFL
     KGEVQFGSWF DHIKGWLRMK GKDNFLFITY EELQQDLQGS VERICGFLGR PLGKEALGSV
     VAHSTFSAMK ANTMSNYTLL PPSLLDHRRG AFLRKGVCGD WKNHFTVAQS EAFDRAYRKQ
     MRGMPTFPWD EDPEEDGSPD PEPSPEPEPK PSLEPNTSLE REPRPNSSPS PSPGQASETP
     HPRPS
//
